Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment

TY - JOUR

T1 - Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment

AU - Bloch, Sara Brandi

AU - la Cour, Morten

AU - Sander, Birgit

AU - Hansen, Louise K H

AU - Fuchs, Josefine

AU - Lund-Andersen, Henrik

AU - Larsen, Michael

N1 - © 2011 The Authors. Acta Ophthalmologica © 2011 Acta Ophthalmologica Scandinavica Foundation.

PY - 2013/2

Y1 - 2013/2

N2 - Purpose: To describe predictors of visual outcome in patients treated with intravitreal ranibizumab for choroidal neovascularisation (CNV) in age-related macular degeneration (AMD). Methods: Retrospective review of 279 patients with CNV in AMD who fulfilled MARINA/ANCHOR study eligibility criteria and were treated with repeated intravitreal injections of ranibizumab 0.5 mg in routine clinical practice, beginning with three initial injections at 4-week intervals followed by individualized retreatment for the subsequent 9 months. Study parameters included best-corrected visual acuity (BCVA) and morphological characteristics. Results: Mean BCVA relative to baseline was +4.7 (p 0.667) Early Treatment Diabetic Retinopathy Study letters after 3, 6 and 12 months, respectively, after a mean of 5.1 injections when the proportion of patients with BCVA =70 letters had doubled compared with baseline. Predictive factors for BCVA =35 letters after 12 months were BCVA =35 letters at baseline and month 3 (p

AB - Purpose: To describe predictors of visual outcome in patients treated with intravitreal ranibizumab for choroidal neovascularisation (CNV) in age-related macular degeneration (AMD). Methods: Retrospective review of 279 patients with CNV in AMD who fulfilled MARINA/ANCHOR study eligibility criteria and were treated with repeated intravitreal injections of ranibizumab 0.5 mg in routine clinical practice, beginning with three initial injections at 4-week intervals followed by individualized retreatment for the subsequent 9 months. Study parameters included best-corrected visual acuity (BCVA) and morphological characteristics. Results: Mean BCVA relative to baseline was +4.7 (p 0.667) Early Treatment Diabetic Retinopathy Study letters after 3, 6 and 12 months, respectively, after a mean of 5.1 injections when the proportion of patients with BCVA =70 letters had doubled compared with baseline. Predictive factors for BCVA =35 letters after 12 months were BCVA =35 letters at baseline and month 3 (p

U2 - 10.1111/j.1755-3768.2011.02268.x

DO - 10.1111/j.1755-3768.2011.02268.x

M3 - Journal article

C2 - 22008284

SN - 1755-375X

JO - Acta Ophthalmologica

JF - Acta Ophthalmologica

ER -